Under the transfer agreement, Sabin has exclusively licensed the technology and acquired patent rights of the potential vaccines.
GSK completed the handover for free, and the National Institutes of Health vaccine research group is stepping in to help with development efforts.
While Ebola is a deadly and highly contagious disease, it is also relatively rare, which makes the potential vaccine market sporadic and likely unprofitable, according to Reuters.
More articles on pharmacy:
Average chief pharmacy officer salary by state
2020 election brewing ‘perfect storm’ for drug-pricing reform, analyst says
Colombia fines Pfizer $25K for drug price inflation
